Vectus Biosystems (ASX:VBS) Short-Term Debt

: A$0.00 Mil (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

Vectus Biosystems's Short-Term Debt for the quarter that ended in Dec. 2022 was A$0.00 Mil.

Vectus Biosystems's quarterly Short-Term Debt declined from Dec. 2021 (A$7.44 Mil) to Jun. 2022 (A$5.89 Mil) and declined from Jun. 2022 (A$5.89 Mil) to Dec. 2022 (A$0.00 Mil).

Vectus Biosystems's annual Short-Term Debt increased from Jun. 2020 (A$0.00 Mil) to Jun. 2021 (A$0.44 Mil) and increased from Jun. 2021 (A$0.44 Mil) to Jun. 2022 (A$5.89 Mil).

Vectus Biosystems Short-Term Debt Historical Data

The historical data trend for Vectus Biosystems's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Short-Term Debt

0.91

0.44

5.89

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
Short-Term Debt										-	0.44	7.44	5.89	-

Vectus Biosystems Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vectus Biosystems Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

http://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines